Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval

PurposeLittle is known about the use of first-line chemotherapy in clinical practice in patients with advanced esophagogastric adenocarcinoma, and no data have been published regarding potential obstacles for the implementation of molecular testing for targeted agents in this patient group. Here, we...

Full description

Bibliographic Details

Main Authors:	Gencer, Deniz (Author) , Hofheinz, Ralf-Dieter (Author)
Other Authors:	Al-Batran, Salah-Eddin (Other) , Dada, Reyad (Other) , Hun͏̈erlitur͏̈koglu, Ali-Nuri (Other) , Gonnermann, Michael (Other) , Kegel, Thomas (Other) , Scheiber, Harald (Other) , Jordan, Wolf-Oliver (Other) , Burkholder, Iris (Other) , Kellermann, Lenka (Other)
Format:	Article (Journal)
Language:	English
Published:	2013
In:	Journal of cancer research and clinical oncology Year: 2012, Volume: 139, Issue: 2, Pages: 337-345
ISSN:	1432-1335
DOI:	10.1007/s00432-012-1335-7
Online Access:	Verlag, Volltext: http://dx.doi.org/10.1007/s00432-012-1335-7 Verlag, Volltext: https://link.springer.com/article/10.1007/s00432-012-1335-7
Author Notes:	Deniz Gencer, Salah-Eddin Al-Batran, Reyad Dada, Ali-Nuri Hünerlitürkoglu, Michael Gonnermann, Thomas Kegel, Harald Scheiber, Wolf-Oliver Jordan, Iris Burkholder, Lenka Kellermann, Ralf-Dieter Hofheinz